Analyst Price Targets — AAPG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 24, 2026 9:22 am | — | Deutsche Bank | $40.00 | $22.34 | TheFly | Ascentage Pharma initiated with a Buy at Deutsche Bank |
| December 4, 2025 11:37 am | Matthew Biegler | Oppenheimer | $45.00 | $30.33 | TheFly | Ascentage Pharma initiated with an Outperform at Oppenheimer |
| November 24, 2025 12:27 pm | Gregory Renza | Truist Financial | $51.00 | $30.64 | TheFly | Ascentage Pharma initiated with a Buy at Truist |
| November 5, 2025 8:40 am | Biren Amin | Piper Sandler | $48.00 | $33.25 | StreetInsider | Piper Sandler Starts Ascentage Pharma Group (AAPG) at Overweight |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for AAPG

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate…

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China.

Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AAPG.
U.S. House Trading
No House trades found for AAPG.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
